Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial

Considering that neutralizing antibody levels induced by two doses of the inactivated vaccine decreased over time and had fallen to low levels by 6 months, and homologous and heterologous booster immunization ...

Source: BMC Infectious Diseases - April 19, 2024 Category: Infectious Diseases Authors: Tao Huang, Qianqian Hu, Xiang Zhou, Huaiyu Yang, Wei Xia, Feng Cao, Minglu Deng, Xiaoxue Teng, Fan Ding, Zaixin Zhong, Lidong Gao, Jiufeng Sun and Lihui Gong Tags: Research Source Type: research